| Project/Area Number |
26670054
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
YOKOTA Takanori 東京医科歯科大学, 医歯(薬)学総合研究科, 教授 (90231688)
|
|---|
| Project Period (FY) |
2014-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
|
|---|
| Keywords | microRNA / microRNA阻害薬 / exon skipping |
|---|
| Outline of Final Research Achievements |
Here we developed a new class of therapeutics oligonucleotide, hetero-chimera-duplex oligonucleotide (HCDO). HCDO has DNA/RNA double strand and antisense oligonucleotide integrated into the RNA strand. We assessed in vivo efficacy of HCDO integrated with microRNA122 inhibitor which had a variety of length of DNA/RNA double strand. We revealed that the length of double strand ranging from 7 to 17mer did not affect efficacy of HCDO. Next, we evaluated in vitro efficacy of HCDO integrated with oligonucleotides regulating splicing. We revealed that HCDO had more efficient ability to regulate splicing than the original single strand oligonucleotide.
|
